期刊论文详细信息
BMC Urology
Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series
Research Article
Stefanie Müller1  Daniel S. Engeler2  Daniel Meyer2  Hans-Peter Schmid2  Dominik Abt2 
[1] Department of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland;Department of Urology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland;
关键词: Sacral neuromodulation;    Sacral nerve stimulation;    Neurologic disease;    Lower urinary tract dysfunction;    Multiple sclerosis;   
DOI  :  10.1186/s12894-015-0102-x
 received in 2015-02-08, accepted in 2015-10-14,  发布年份 2015
来源: Springer
PDF
【 摘 要 】

BackgroundSacral neuromodulation is well established in the treatment of refractory, non-neurogenic lower urinary tract dysfunction, but its efficacy and safety in patients with lower urinary tract dysfunction of neurological origin is unclear. Only few case series have been reported for multiple sclerosis. We prospectively evaluated the efficacy and safety of sacral neuromodulation in patients with multiple sclerosis.MethodsSeventeen patients (13 women, 4 men) treated with sacral neuromodulation for refractory neurogenic lower urinary tract dysfunction caused by multiple sclerosis were prospectively enrolled (2007–2011). Patients had to have stable disease and confirmed neurogenic lower urinary tract dysfunction. Voiding variables, adverse events, and subjective satisfaction were assessed.ResultsSixteen (94 %) patients had a positive test phase with a >70 % improvement. After implantation of the pulse generator (InterStim II), the improvement in voiding variables persisted. At 3 years, the median voided volume had improved significantly from 125 (range 0 to 350) to 265 ml (range 200 to 350) (p < 0.001), the post void residual from 170 (range 0 to 730) to 25 ml (range 0 to 300) (p = 0.01), micturition frequency from 12 (range 6 to 20) to 7 (range 4 to 12) (p = 0.003), and number of incontinence episodes from 3 (range 0 to 10) to 0 (range 0 to 1) (p = 0.006). The median subjective degree of satisfaction was 80 %. Only two patients developed lack of benefit. No major complications occurred.ConclusionsChronic sacral neuromodulation promises to be an effective and safe treatment of refractory neurogenic lower urinary tract dysfunction in selected patients with multiple sclerosis.

【 授权许可】

CC BY   
© Engeler et al. 2015

【 预 览 】
附件列表
Files Size Format View
RO202311090694111ZK.pdf 564KB PDF download
【 参考文献 】
  • [1]
  • [2]
  • [3]
  • [4]
  • [5]
  • [6]
  • [7]
  • [8]
  • [9]
  • [10]
  • [11]
  • [12]
  • [13]
  • [14]
  • [15]
  • [16]
  • [17]
  • [18]
  • [19]
  • [20]
  • [21]
  • [22]
  • [23]
  • [24]
  • [25]
  • [26]
  • [27]
  文献评价指标  
  下载次数:11次 浏览次数:0次